Company news

Mesoblast Limited news in 2017

Mesoblast Limited's news releases, calls and decks from 2017, newest first.

View company

Mesoblast Receives RMAT For LVAD Heart Failure Patients

December 21, 2017

Mesoblasts P3 GVHD Trial Completes Enrollment

December 19, 2017

Mesoblast Grants TiGenix License For Treatment of Fistulae

December 14, 2017

MSB Named Global Technology Leader In Cell Therapy Industry

December 7, 2017

Response to ASX Aware Letter Query

November 16, 2017

Mesoblast Provides Corporate Update and Q1 Financial Results

November 14, 2017

RA Phase 2 Trial Results Presented At ACR Annual Meeting

November 12, 2017

End-Stage Heart Failure Trial Completes Enrollment

September 27, 2017

Mesoblast Corporate Updates at Healthcare Conferences

September 25, 2017

Retail Entitlement Offer

August 31, 2017

Underwritten A$50.7M Raise Closes Institutional Allocation

August 29, 2017

Fully Underwritten A$50.7 Million Entitlement Offer

August 25, 2017

Potential For Accelerated Market Entry In Advanced CHF

August 23, 2017

Positive Results of MSB Therapy in Osteoarthritis Published

August 16, 2017

Mesoblast RA Results Presented At EULAR Congress

June 22, 2017

MSB Provides Q3 Operational Highlights and Financial Results

May 24, 2017

Third Quarter Financial Results On Form 6-K

May 24, 2017

Successful Interim Analysis in Phase 3 Heart Failure Trial

April 9, 2017

Mesoblast Receives A$3.7m From Aus Govt For R&D

April 5, 2017

FDA Clears Heart Disease Trial At Boston Childrens Hospital

April 3, 2017

Process Initiated For CHF P3 Interim Analysis

March 30, 2017

Mesoblast Raises US$40 Million

March 26, 2017

Durable Three Year Outcomes in Disc Disease

March 15, 2017

FDA Grants Mesoblast Fast Track Designation For GVHD

March 6, 2017

Positive Nine Month RA Results For Mesoblast Cell Therapy

February 15, 2017

Published Results Show MSB Cells Effective In RA Model

February 13, 2017

Mesoblast Director Recognized For Cardiovascular Leadership

January 30, 2017

Decks in 2017